Fig. 3: Survival analysis of patients with S-HITOC. | Nature Communications

Fig. 3: Survival analysis of patients with S-HITOC.

From: Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study

Fig. 3

A PFS among all patients (N = 45); B OS among all patients (N = 45); C PFS based on the PTI score [N = 45, N (PTI score > 10) = 5, N (PTI score ≤ 10) = 40]; D PFS based on the surgical resection completeness [N = 45, N (R2) = 14, N (R0/R1) = 31]; E PFS based on the pleural dissemination classification [N = 45, N (DNT) = 12, N (TPR < 5 year)=17, N (TPR ≥ 5 year)=16]; F PFS based on the tumor stage [N = 45, N (IVA) = 40, N (IVB) = 5]. PFS progression-free survival, OS overall survival, PTI pleural tumor index, R0 complete cytoreductive surgery without residual visible disease, R1 optimal cytoreductive surgery with residual tumors measuring no more than 10 mm, R2 incomplete cytoreductive surgery with residual lesions measuring > 10 mm in diameter, DNT de novo Masaoka stage IVA TETs, TPR TETs with pleural recurrence, HR hazard ratio, CI confidence interval.

Back to article page